News & Stories

After clinical trial hold and plunging stock, what's next for Juno Therapeutics?

July 11, 2016 / 3:19 pm

Bill Radke speaks with Luke Timmerman about what went wrong during Seattle-based Juno Therapeutics' clinical trial of an immunotherapy treatment for leukemia and what it might mean for the company.

Why you can trust KUOW

Bill Radke
Host

Bill hosts Week In Review and Words in Review. After starting with KUOW as a University of Washington student in 1985, Bill was KUOW's morning host in the '90s and the creator of past show, Rewind, a news-satire show heard on KUOW and nationwide on NPR. Bill moved away to Southern California to host American Public Media's Weekend America and Marketplace Morning Report and returned to KUOW in 2012.
More stories from Bill Radke »
Posey Gruener
Producer, The Record

Posey coordinates on-air news coverage for KUOW's midday newsmagazine. Before joining KUOW, Posey worked at WNYC as a producer for The Takeaway, a live daily news program, and Studio 360, a weekly show about creativity, pop culture and the arts. She has also worked for The Moth, the live storytelling organization, and StoryCorps, the oral history radio project. Her freelance work has aired on Studio 360 and All Things Considered. Posey graduated Summa Cum Laude from Grinnell College in Grinnell, Iowa. She holds a certificate in writing from the Salt Institute for Documentary Studies in Portland, Maine, and a certificate in audio production from the Center for Documentary Studies in Durham, North Carolina.
More stories from Posey Gruener »

Get Local Stories

Delivered to your inbox daily, weekly, or monthly.

Explore Newsletters

After clinical trial hold and plunging stock, what's next for Juno Therapeutics?

Host

Producer, The Record

Get Local Stories

Delivered to your inbox daily, weekly, or monthly.